{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:24:57Z","timestamp":1790151897748,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00259-013-2658-6","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T17:12:16Z","timestamp":1389892336000},"page":"867-877","source":"Crossref","is-referenced-by-count":35,"title":["Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Luigi","family":"Aloj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Aurilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Frigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corradina","family":"Caraco\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans D.","family":"Menssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"key":"2658_CR1","doi-asserted-by":"crossref","unstructured":"Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2011:(8):CD007941. doi: 10.1002\/14651858.CD007941.pub2","DOI":"10.1002\/14651858.CD007941.pub2"},{"key":"2658_CR2","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","volume":"117","author":"J Kuruvilla","year":"2011","unstructured":"Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208\u201317.","journal-title":"Blood"},{"key":"2658_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2012.04.001","volume":"26","author":"J Uhm","year":"2012","unstructured":"Uhm J, Kuruvilla J. Treatment of newly diagnosed advanced stage Hodgkin lymphoma. Blood Rev. 2012;26:167\u201374.","journal-title":"Blood Rev"},{"key":"2658_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.06998.x","volume":"141","author":"P Brice","year":"2008","unstructured":"Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2008;141:3\u201313.","journal-title":"Br J Haematol"},{"key":"2658_CR5","unstructured":"Horning S, Fanale M, deVos S, Borchmann P, Illidge T, Engert A, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract 118]. Ann Oncol. 2008;19 Suppl 4:120\u20131"},{"key":"2658_CR6","doi-asserted-by":"crossref","unstructured":"Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:507\u201319. doi: 10.1182\/asheducation-2009.1.507","DOI":"10.1182\/asheducation-2009.1.507"},{"key":"2658_CR7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2011.03.005","volume":"24","author":"T Illidge","year":"2011","unstructured":"Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:279\u201393.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2658_CR8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441\u20139.","journal-title":"N Engl J Med"},{"key":"2658_CR9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","volume":"31","author":"CW Scholz","year":"2013","unstructured":"Scholz CW, Pinto A, Linkesch W, Linden O, Viardot A, Keller U, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308\u201313.","journal-title":"J Clin Oncol"},{"key":"2658_CR10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/pmic.200401273","volume":"5","author":"M Silacci","year":"2005","unstructured":"Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5:2340\u201350.","journal-title":"Proteomics"},{"key":"2658_CR11","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-05-2804","volume":"12","author":"SS Brack","year":"2006","unstructured":"Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res. 2006;12:3200\u20138.","journal-title":"Clin Cancer Res"},{"key":"2658_CR12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ijc.2910520504","volume":"52","author":"L Borsi","year":"1992","unstructured":"Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1992;52:688\u201392.","journal-title":"Int J Cancer"},{"key":"2658_CR13","doi-asserted-by":"crossref","first-page":"7053s","DOI":"10.1158\/1078-0432.CCR-1004-0015","volume":"11","author":"D Berndorff","year":"2005","unstructured":"Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s\u201363s.","journal-title":"Clin Cancer Res"},{"key":"2658_CR14","doi-asserted-by":"crossref","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","volume":"273","author":"A Pini","year":"1998","unstructured":"Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769\u201376.","journal-title":"J Biol Chem."},{"key":"2658_CR15","first-page":"1127","volume":"47","author":"BM Tijink","year":"2006","unstructured":"Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127\u201335.","journal-title":"J Nucl Med"},{"key":"2658_CR16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.111.101006","volume":"53","author":"PA Erba","year":"2012","unstructured":"Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med. 2012;53:922\u20137.","journal-title":"J Nucl Med"},{"key":"2658_CR17","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","volume":"113","author":"S Sauer","year":"2009","unstructured":"Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265\u201374.","journal-title":"Blood"},{"key":"2658_CR18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2967\/jnumed.112.111310","volume":"54","author":"DA Heuveling","year":"2013","unstructured":"Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54:397\u2013401.","journal-title":"J Nucl Med"},{"key":"2658_CR19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","volume":"221","author":"D Aldinucci","year":"2010","unstructured":"Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221:248\u201363.","journal-title":"J Pathol"},{"key":"2658_CR20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812\u201326.","journal-title":"J Clin Oncol"},{"key":"2658_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11899-010-0052-z","volume":"5","author":"Y Oki","year":"2010","unstructured":"Oki Y, Younes A. Does rituximab have a place in treating classic Hodgkin lymphoma? Curr Hematol Malig Rep. 2010;5:135\u20139.","journal-title":"Curr Hematol Malig Rep."},{"key":"2658_CR22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0344-0338(11)81254-9","volume":"188","author":"Y Soini","year":"1992","unstructured":"Soini Y, Alavaikko M, Lehto VP, Virtanen I. Tenascin in reactive lymph nodes and in malignant lymphomas. Pathol Res Pract. 1992;188:1078\u201382.","journal-title":"Pathol Res Pract"},{"key":"2658_CR23","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-01-405456","volume":"119","author":"A Younes","year":"2012","unstructured":"Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012;119:4123\u20138.","journal-title":"Blood"},{"key":"2658_CR24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","volume":"98","author":"A Younes","year":"2003","unstructured":"Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98:310\u20134.","journal-title":"Cancer"},{"key":"2658_CR25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.1900","volume":"208","author":"D Khnykin","year":"2006","unstructured":"Khnykin D, Troen G, Berner JM, Delabie J. The expression of fibroblast growth factors and their receptors in Hodgkin\u2019s lymphoma. J Pathol. 2006;208:431\u20138.","journal-title":"J Pathol"},{"key":"2658_CR26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/labinvest.3700672","volume":"87","author":"JC Wallentine","year":"2007","unstructured":"Wallentine JC, Kim KK, Seiler 3rd CE, Vaughn CP, Crockett DK, Tripp SR, et al. Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS\/MS. Lab Invest. 2007;87:1113\u201324.","journal-title":"Lab Invest."},{"key":"2658_CR27","doi-asserted-by":"crossref","unstructured":"Aloj L, D\u2019Ambrosio L, Aurilio M, Marreno R, Menssen HD, Giovannoni L, et al. Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts. Vol 29, No. 15 suppl, 8063; 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.8063"},{"key":"2658_CR28","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S\u201361S.","journal-title":"J Nucl Med."},{"key":"2658_CR29","first-page":"2167","volume":"39","author":"WC Buijs","year":"1998","unstructured":"Buijs WC, Siegel JA, Boerman OC, Corstens FH. Absolute organ activity estimated by five different methods of background correction. J Nucl Med. 1998;39:2167\u201372.","journal-title":"J Nucl Med"},{"key":"2658_CR30","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"2658_CR31","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689\u201394.","journal-title":"J Nucl Med"},{"key":"2658_CR32","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1088\/0031-9155\/52\/17\/009","volume":"52","author":"AC Traino","year":"2007","unstructured":"Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52:5231\u201348.","journal-title":"Phys Med Biol"},{"key":"2658_CR33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2658_CR34","first-page":"65","volume":"3","author":"J Folkman","year":"1992","unstructured":"Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65\u201371.","journal-title":"Semin Cancer Biol"},{"key":"2658_CR35","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjc.6605238","volume":"101","author":"A Birgersdotter","year":"2009","unstructured":"Birgersdotter A, Baumforth KR, Porwit A, Sjoberg J, Wei W, Bjorkholm M, et al. Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin\u2019s lymphoma. Br J Cancer. 2009;101:1393\u2013401.","journal-title":"Br J Cancer"},{"key":"2658_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1309\/AJCPG7H0SSRYKNKH","volume":"133","author":"A Birgersdotter","year":"2010","unstructured":"Birgersdotter A, Baumforth KR, Wei W, Murray PG, Sjoberg J, Bjorkholm M, et al. Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. Am J Clin Pathol. 2010;133:271\u201380.","journal-title":"Am J Clin Pathol"},{"key":"2658_CR37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/14737140.7.5.735","volume":"7","author":"D Buglio","year":"2007","unstructured":"Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther. 2007;7:735\u201340.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2658_CR38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.blre.2010.08.003","volume":"24","author":"A Jona","year":"2010","unstructured":"Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24:233\u20138.","journal-title":"Blood Rev"},{"key":"2658_CR39","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2658-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2658-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2658-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T18:17:18Z","timestamp":1565115438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2658-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2658"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2658-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,17]]}}}